This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

10 Biotech Trades for Second Half of 2011

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Sangamo Biosciences (SGMO - Get Report)
The event: Phase IIb study of SB-509 in diabetic neuropathy.
The timeline: Top-line results to be announced in the second half of 2011.
The stakes: The legitimacy of zinc-finger drug technology, which Sangamo has been developing for years on its own. SB-509 is an engineered protein, or "zinc finger," specifically designed to turn on a gene to restart nerve growth. Previously reported data from earlier studies of SB-509 in diabetic neuropathy have produced mixed results and a significant level of investor skepticism about the technology.

Sangamo has the opportunity with the looming results from the phase IIb study in diabetic neuropathy to silence the critics and push SB-509 and the entire zinc-finger drug technology platform forward into pivotal late-stage studies and perhaps lucrative partnership deals. To get there, the data from the study need to demonstrate that SB-509 can improve the health and function of damaged nerves.
2 of 11

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
BPAX $55.05 -1.24%
TSPT $30.00 0.67%
EXEL $6.05 0.00%
GILD $107.78 0.00%
ONTY $3.54 0.00%


Chart of I:DJI
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 +1.21 0.06%
NASDAQ 4,828.3250 +15.6170 0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs